In a joint venture, German biopharmaceutical firm BioNTech and Genevant Sciences, a genetic disorder therapeutics maker plan to develop mRNA therapy programmes targeting rare diseases with severely deficient medical attention.
Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
The FoI request was sent by enterprise IT firm Intercity Technology to as many as 143 NHS trusts in England. Out of these, 80 responded, of which 25 reported outages across their IT systems during the period from January 2015 to February 2018.
A study report published in Nature's Digital Medicine partner journal shows that the wearable monitor Fitbit Charge HR could assess the health condition of cancer patients and predict their adverse events.
Cerner and Lumeris have brought together their technologies to result in EHR agnostic. The Kansas City, Missouri-based Cerner specializes in EHRs and other IT solutions whereas the St. Louis, Missouri-based Lumeris’ technique involves value-based care.
San Jose-based Immersion announced in a statement that it has settled its dispute with Fitbit more or less a year after filing a suit in the U.S. District Court for the Northern District of California. However, the two companies have not disclosed their terms of settlement and license agreement.
As a result of the high demand for GlaxoSmithKline's new shingles vaccine, Shingrix, two U.S. senators have urged the pharma giant to boost inventory levels on facing a shortage in the supplies even after the company established their "fair and equitable" process to ship Shingrix doses.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.